Concepedia

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark,

The Lancet Oncology · 2020 · 898 citations · 25 references

DOI

Concepts

References

25

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

, , +10

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

, , +14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

, , +17

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

, , +12

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

, , +16